LOS ANGELES, Sept. 26, 2014 /PRNewswire/
-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE
MKT: IMUC) today announced that Andrew
Gengos, Chief Executive Officer, will present a corporate
overview and business update at the Livingston Securities
7th Annual Life Sciences Stakeholders Summit at
1:55 pm ET on Wednesday, October 1, 2014, at the Cira Center in
Philadelphia, PA.
To access the live audio webcast of the Livingston Securities
presentation, please log on through a link located in the Investors
section of ImmunoCellular's website at www.imuc.com, under the
Events & Presentations tab. The event can also be accessed at:
https://www1.gotomeeting.com/join/656225217; (571) 317-3112, Access
Code 656-225-217. The audio PIN will be shown after joining the
meeting using meeting ID 656-225-217. A replay of the presentation
will be available.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company
that is developing immune-based therapies for the treatment of
brain and other cancers. ImmunoCellular has concluded a phase II
trial of its lead product candidate, ICT-107, a dendritic
cell-based vaccine targeting multiple tumor-associated antigens for
glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a
dendritic cell vaccine targeting CD133, ICT-140, a dendritic cell
vaccine targeting ovarian cancer antigens and cancer stem cells and
a preclinical antigen-specific T-cell therapy program. To learn
more about ImmunoCellular, please visit www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
SOURCE ImmunoCellular Therapeutics, Ltd.